期刊文献+

重酒石酸长春瑞滨脂质微球注射液的制备 被引量:1

Preparation technology of vinorelbine bitartrate lipid microsphere for injection
在线阅读 下载PDF
导出
摘要 目的研制重酒石酸长春瑞滨脂质微球注射液。方法通过高压均质使乳粒产生高速碰撞和空穴作用,降低乳粒直径,并控制高压均质的压力和次数来提高稳定性。结果重酒石酸长春瑞滨脂质微球注射液的平均粒径为200 nm,包封率为85%,具有良好的稳定性。结论经过制剂稳定性实验及动物安全性实验,表明采用上述制备工艺制备的脂质微球注射液具有一定的稳定性和安全性。 Objective To prepare the vinorelbine bitartrate lipid microsphere for injection. Methods The particle size of the lipid microsphere for injection was significantly reduced by high pressure homogenizer, which mad of fro 1 1 e particles of the lipid microsphere for injection produce high speed impacts and cavitation, The stability pid mierosphere for injection was improved when the homogenizing pressure and cycles were well coned during high pressure homogenization process. Results The particle size of vinorelbine bitartrate lipid microsphere for injection was about 200 nm. The Incorporation radio was 85 %. The vinordbine bitartrate lipid microsphere for injection has got a good stability. Conclusions The stability and rat security tests indicate that the preparation technology of lipid microsphere for injection is reasonable and feasible.
出处 《沈阳药科大学学报》 CAS CSCD 北大核心 2006年第12期749-753,共5页 Journal of Shenyang Pharmaceutical University
关键词 重酒石酸长春瑞滨 脂质微球 稳定性 脂质微球安全性 vinorelbine bitartrate lipid microsphere stability lipid microshpere security
  • 相关文献

参考文献10

二级参考文献27

  • 1潘启超.长春碱类的新进展──失碳长春碱[J].癌症,1996,15(3):228-231. 被引量:276
  • 2周际昌.实用肿瘤内科学[M].北京:人民卫生出版社,1998.463.
  • 3Le Chevalier T, Brisgand D, Soria JC, et al. Long term analysis of survial in the European randomized trial comparing vinorelbine alone in advanced non - small cell lung cancer.Oncologist,2001,61:8-11.
  • 4Bidoli P, Slani S, Candis D, et al. Single-agent chemotherapy with vinorelbine for pretreated or metastatic squamous cell carcinoma of the esophagus[J]. Tumori, 2001,87(5) :299 - 302.
  • 5Conroy T, Etienne PL, Adenis A, et al. Vinorelbine and cisplatin in metastatic squamous cell carcinoma of the esophagus: response, toxility,quality of life and survival[J]. Ann Oncol, 2002,13(5):721 -729.
  • 6Barutca S, Ceyhan C, Meydan N, et al. A new perspective on cardiotoxicity of 5-fluorouracil [ J ]. Chemotherapy, 2004,50( 3 ): 113 - 118.
  • 7Raycoquard I, Bironp, Bachelot T,et al,Vinorelbine and Cisplatin(CIV1C regimen)for the treatment of metastatic breast carcinoma after failure of anthracycline and(or) Paclitaxel containing regimens[J]. Cancer, 1998, 82(1) :134- 138.
  • 8Non-small Cell Lung Cancer Collabortive Group . Chemotherapy in non-samall-cell lung cancer :a meta-analysis using up-dated data on individual patients from 52 randomized clinical trials[ J]. BMJ,1995 ,311(8) :899
  • 9Spain RC. Neoadjuvant mitomycin C, cisplatin, and infusion vinblastine in locally and regionally advanced nonsmall cell lung cancer: problems and progress from the perspective of long term follow-up[J]. Semi Oncol, 1998,15(3):3
  • 10沈瑜 殷蔚伯 谷铣之 主编.临床放射生物学[A].殷蔚伯,谷铣之,主编.肿瘤放射治疗学[M]:第三版[C].北京:中国协和医科大学出版社,2002.264-295.

共引文献23

同被引文献27

引证文献1

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部